11/5/2026

speaker
Operator
Conference Call Operator

Good afternoon, everyone, and thank you for standing by. Welcome to the Corvus Pharmaceuticals 3rd Quarter 2026 Business Update and Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session, and instructions will follow at that time. It is now my pleasure to turn the call over to Zach Kubo, Vice President, Investor Relations and Corporate Communications. Please go ahead, sir.

speaker
Zach Kubo
Vice President, Investor Relations and Corporate Communications

Thank you, operator, and good afternoon, everyone. Thanks for joining us for the Corvus Pharmaceuticals Third Quarter 2026 Business Update and Financial Results Conference Call. On the call to discuss the results and business updates are Richard Miller, Chief Executive Officer, Leif Lee, Chief Financial Officer, Jeff Arcara, Chief Business Officer, Ben Jones, Senior Vice President of Pharmaceutical Development, and Suresh Mahabashyam, Vice President of Clinical Development. The executive team will open the call with some prepared remarks followed by a question and answer period. I would like to remind everyone that comments made by management today and answers to questions will include forward-looking statements. Forward-looking statements are based on estimates and assumptions as of today and are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied by those statements, including the risks and uncertainties described in the Corvus Quarterly Report on Form 10-Q for the quarter ended September 30, 2026, and other filings the company makes with the SEC from time to time. The company undertakes no obligation to publicly update or revise any forward-looking statements except as required by law. With that, I'd like to turn the call over to Leif Lee. Leif?

speaker
Leif Lee
Chief Financial Officer

Thank you, Zach. I will begin with a brief overview of our third quarter 2026 financials and then turn the call over to Richard for a business update. Research and development expenses in the third quarter of 2026 total $17.8 million compared to $8.5 million for the same period in 2025. The increase in R&D expenses was primarily due to higher clinical trial costs associated with the development of socalidinib as well as an increase in personnel costs. Net loss for the third quarter of 2026 was $20.3 million compared to a net loss of $10.2 million for the same period in 2025. Included in the net loss for the third quarter of 2026 and 2025 were non-cash losses of 0.9 million and 0.3 million respectively from Corvus's equity method investment in Angel Pharmaceuticals. Total stock compensation expense for the three months ended September 30th, 2026 was $2.8 million compared to $1.2 million for the same period in 2025. As of September 30th, 2026, Chorus had cash, cash equivalents, and marketable securities totaling $202.9 million as compared to $56.8 million at December 31st, 2025. Cash as of September 30th, 2026 included approximately $189.4 million in net proceeds received in a follow-on offering completed in Q1. also has announced on June 9th, 2026, Corvus invested $5 million in a $13.5 million financing completed by Angel Pharmaceuticals in the second quarter of 2026. Based on our cash position at September 30th, 2026, and our current plans, we expect our cash to fund operations into the second quarter of 2028. I'll now turn the call over to Richard, who will discuss our clinical progress and elaborate on our strategy and plans.

Want transcripts like this in your own app? Try the Earnings call API, or read the transcript API docs.

Disclaimer

This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.

-

-

Use this data in your own app

Pull this call's transcript, audio and slides with the Earnings call transcripts API.

See pricing

9,000+ companies · REST API